RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma

Oncogene

Volumn 29, Issue 39, 2010, Pages 5404-5415

  Zhang, Y ^a   Jiang, X ^a   Qin, X ^b   Ye, D ^b   Yi, Z ^c   Liu, M ^c   Bai, O ^d   Liu, W ^a   Xie, X ^a   Wang, Z ^a   Fang, J ^a   Chen, Y ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

Author keywords

Angiogenesis; CcRCC; HIF 1 ; P300; RKTG; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; RAF KINASE TRAPPING TO GOLGI; RAF PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RKTG PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; DOWN REGULATION; ENDOTHELIUM CELL; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AUTOCRINE COMMUNICATION; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; RAF KINASES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77957564884     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.270     Document Type: Article

References (39)

1. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. (2003). Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301: 94-96.
2. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973.
3. Dougher M, Terman BI. (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18: 1619-1627.
4. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K et al. (1999). Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914.
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al.. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
6. Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y et al. (2008). RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. Carcinogenesis 29: 1157-1163.
7. Feng L, Xie X, Ding Q, Luo X, He J, Fan F et al. (2007). Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci USA 104: 14348-14353.
8. Ferrara N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611. (Pubitemid 39099316)
9. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. (1995). Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270: 25915-25919.
10. Guo D, Jia Q, Song HY, Warren RS, Donner DB. (1995). Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733.
11. Haas CS, Amin MA, Allen BB, Ruth JH, Haines III GK, Woods JM et al. (2006). Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54: 2402-2414.
12. Hur E, Chang KY, Lee E, Lee SK, Park H. (2001). Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxiainducible factor-1alpha. Mol Pharmacol 59: 1216-1224.
13. Iliopoulos O, Kibel A, Gray S, Kaelin Jr WG. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
14. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW et al. (1999). Identification of the von Hippel-lindau tumorsuppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441.
15. Kallio PJ, Okamoto K, OBrien S, Carrero P, Makino Y, Tanaka H et al. (1998). Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 17: 6573-6586.
16. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S et al. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130: 691-703.
17. Levy AP, Levy NS, Wegner S, Goldberg MA. (1995). Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333-13340.
18. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. (1999). The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13: 1822-1833.
19. Liu Y, Cox SR, Morita T, Kourembanas S. (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 50 enhancer. Circ Res 77: 638-643.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
21. Lohela M, Bry M, Tammela T, Alitalo K. (2009). VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
22. Luo X, Feng L, Jiang X, Xiao F, Wang Z, Feng GS et al. (2008). Characterization of the topology and functional domains of RKTG. Biochem J 414: 399-406.
23. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. (2003). Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3: 75-88.
24. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P et al. (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24: 2342-2353.
25. Matsumoto T, Mugishima H. (2006). Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb 13: 130-135.
26. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
28. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375: 577-581.
29. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A et al. (2006). Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxiainducible factor-1alpha. J Biol Chem 281: 33095-33106.
30. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. (2003).MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278: 14013-14019.
31. Srivastava RK, Unterman TG, Shankar S. (2009). FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 337: 201-212.
32. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP et al. (2004). Loss of HIF-1alpha in endothelial cells disrupts a hypoxiadriven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-495.
33. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K et al. (2001). Spred is a Sprouty-related suppressor of Ras signalling. Nature 412: 647-651.
34. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA et al. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
35. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
36. Wu LW,Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA et al. (2000). Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275: 5096-5103.
37. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS et al. (1996). Characterization of vascular endothelial growth factors effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026.
38. Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang Z et al. (2008). Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis 29: 1632-1638.
39. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB et al. (2008). Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 68: 1843-1850.